Novel Domain V mutation in *cfr*-positive clinical *Staphylococcus haemolyticus*

isolates causing linezolid resistance in Egyptian ICU patients

Saber Maghraby[1], Mohamed Ez El-Din Dawoud[1], Mohamed Eweis[1], Abdullah El-

nagish[2*], Doaa Gaith[3]

[1] Department of Botany and Microbiology, Faculty of Science, Cairo University,

Cairo, Egypt

[2] Department of Botany and Microbiology, Faculty of Science, Sohag University,

82524 Sohag, Egypt

[3] Clinical and Chemical Pathology Department, Faculty of Medicine, Cairo

University, Cairo, Egypt

*Corresponding author: ael.nagish@science.sohag.edu.eg

Abstract

Linezolid resistance has become a focal point worldwide, particularly as

linezolid stands as one of the last resort antibiotics against multiple-drug resistant

bacterial strains. Despite its critical importance, the situation in Egypt remains

relatively unexplored. As various linezolid resistance mechanisms have been

identified in staphylococci, our investigation aims to uncover the molecular

characteristics of staphylococci showing reduced susceptibility to Linezolid at Kasr-

El-Eini Teaching Hospital. Thirty isolates were investigated in this study. The

selected samples, identified by Vitek 2 system and confirmed by 16S rRNA, were

examined by disc diffusion method. Of the 30 isolates, two were confirmed as

linezolid resistant and screened for the presence of cfr gene and mutations in the

Domain V of the 23S rRNA gene. Both of the studied strains, identified as

Staphylococcus haemolyticus, SZ-2 and SZ-7 harbored two point mutations G2576T

and G2602T in the Domain V of the 23S rRNA gene. A novel G2694C mutation

reported for the first time was detected in strain SZ-7. The presence of cfr gene was

confirmed in both isolates. Linezolid-resistant *Staphylococcus haemolyticus* had

emerged in ICU patients with prior antibiotic exposure. The exact role of the novel

G2694C mutation in linezolid resistance needs further investigations. The study

underscores the importance of proper surveillance of *cfr*-carrying strains in the

healthcare settings in Egypt.

Keywords

Linezolid, Resistance, Domain V, 23S rRNA, Mutations, Staphylococcus

haemolyticus

Introduction

Staphylococcus haemolyticus, a coagulase-negative staphylococci (CoNS),

naturally resides in the human skin tissue microbiota with the potential to induce

various illnesses, such as skin infections, bloodstream infections, and other several

nosocomial infections [1]. In recent years, broad-spectrum antibacterials were widely

used in clinical settings, that led to a persistent rise in drug resistance. The current

surge in bacterial drug resistance is a cause for serious concern [2]. Linezolid, an

oxazolidinone antibiotic, was approved for clinical use in 2000 [3]. This antibiotic is

potent against multidrug-resistant Gram-positive bacteria, including methicillin-

resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant Enterococci (VRE),

and *Streptococcus pneumoniae* [4]. Activity of linezolid results from binding to the

23S rRNA in the 50S ribosomal subunit. Thus, it acts as an inhibitor of protein

synthesis by binding to the ribosomal peptidyl transferase center (PTC) affecting

tRNA positioning and eventually stopping the growth of bacteria [5,6].

The prevalence of linezolid resistance is steadily on the rise due to the

extensive utilization of this antibiotic. Numerous reports have documented cases of

linezolid-resistant staphylococci. The most well-established mechanisms underlying

the development of linezolid-resistant staphylococci involves a mutation in the 23S

rRNA gene target and the acquisition of the chloramphenicol-florfenicol resistance

(cfr) gene [7,8,9,10]. The 23S rRNA, a constituent of the bacterial ribosome 50S

subunit, can undergo mutations during exposure to linezolid, rendering the drug

ineffective and ultimately resulting in drug resistance. Additionally, gene mutation

sites exhibit variability among different strains [10, 11]. Among Staphylococcus

strains, G2576T gene mutation is the most prevalent [11,12,13,14]. cfr gene, first

identified in plasmids of Staphylococcus isolates from German cows, encodes a

methyltransferase capable of modifying 23S rRNA [15]. The cfr gene facilitates

methylation at specific sites on the ribosomal large subunit, leading to resistance

against linezolid [5,16].

At our Kasr-El-Eini Teaching Hospital, the escalating concern lies in

staphylococcal isolates in the intensive care units, which exhibit an extraordinary

predisposition to develop resistance to all available antibiotics including linezolid.

Consequently, in pursuit of viable treatment alternatives, there is a pressing need to

comprehend the resistance mechanism of such isolates. Henceforth, this study was

undertaken to investigate the molecular characteristics of linezolid-resistant S.

haemolyticus identified in clinical infections. A collection of linezolid-resistant CoNS

(LRCoNS) from 30 patients were evaluated for mechanisms of linezolid resistance.

Materials and Methods

Sample collection, identification and antimicrobial susceptibility testing of bacterial isolates

Over two years; from March 2020 to March 2022, a total of 30 clinical isolates of staphylococci showing reduced susceptibility to Linezolid were collected from Kasr El-Eini Teaching Hospital. Samples were isolated from different specimens, including pus and blood. Disc diffusion method was used to screen isolates for linezolid resistance. Linezolid concentration used was 30 µg. The antimicrobial discs were obtained from Oxoid Ltd (Basingstoke, Hampshire, England, UK) and processed according to the manufacturer's instructions.

The identification of isolates was performed using conventional techniques such as cultivation on mannitol salt agar [17] and deoxyribonuclease (DNase) agar [18]. The isolates were further identified using VITEK 2 system (bioMérieux, Marcy-l'Étoile, France) using the VITEK 2 GP Card according to the manufacturer's instructions. The antibiotic susceptibility test of isolates was performed on Mueller Hinton agar using the Kirby Bauer disc diffusion method [19] as per Clinical and Laboratory Standard Institute [20] guidelines using antibiotic Linezolid 30 µg. Subsequently, identification of the selected bacterial isolates was confirmed by 16S rRNA gene [21]. All the relevant clinical data were collected for analysis, including dose and length of linezolid treatments and other results of antimicrobial susceptibility tests.

Mechanisms of linezolid resistance among the isolates

The two most resistant *Staphylococcus haemolyticus* strains (namely SZ-2 and SZ-7) were selected and screened for point mutations in Domain V of the 23S rRNA

gene and the presence of the *cfr* gene by PCR and DNA sequencing as described

previously [7,8,9,10].

The genomic DNA was isolated using Quick-DNA™ Miniprep Kit from

Zymo Research™ according to the manufacturer instruction manual. Amplification

was performed using the following PCR conditions: 35 cycles of denaturing,

annealing, and extension at 94°C (30 s), 55°C (30 s), and 72°C (1 min) respectively;

and a final 10-min extension at 72°C.

To elucidate the mechanism of linezolid resistance, screening for cfr gene and

point mutations in domain V of 23S rRNA gene were investigated by amplifying the

loci using the PCR conditions described by Yoo et al [8]. Amplification by PCR was

performed using primers listed in Table 1. Amplicons were sequenced on both strands

and sequences were aligned with the corresponding sequences from linezolid-

susceptible *S. haemolyticus* JCSC 1435 (GenBank accession No. AP006716). All

sequenced data was uploaded to the NCBI under accession numbers shown in the data

availability section.

Table 1. Primers are used for PCR amplification of targeted genes.

Target genes	Primer name	Sequence (5′–3′)	Product size (bp)	Reference
Domain V of the 23S rRNA	23S_rRNA_Fw	5′-GCGGTCGCCTCCTAAAAG-3′	390	[22]
	23S_rRNA_Rv	5′-ATCCCGGTCCTCTCGTACTA-3′		
cfr gene	*cfr*-Fw	5′-TGAAGTATAAAGCAGGTTGGGAGTCA-3′	746	[23]
	cfr-Rv	5′-ACCATATAATTGACCACAAGCAGC-3′		

Results and Discussion

Twenty four of the total 30 isolates were found to be totally susceptible to linezolid. Isolates SZ-2 and SZ-7, showed the highest resistance to linezolid, were selected for further investigations. The two isolates were identified as Staphylococcus based on their characteristic growth on blood agar and microscopic observations. The isolates were negative for mannitol fermentation, DNase and coagulase test, thus confirming coagulase negative Staphylococcus. The Vitek 2 system identified the isolates correctly (Table 2), with a probability of 99% and confidence level 'excellent'. The 16S rRNA gene sequence revealed that the isolates are S. haemolyticus with 99% similarity with S. haemolyticus strain JCSC1435 in BLAST search.

Strain SZ-2, with a linezolid inhibition zone diameter (IZD) less than 1 mm (zone diameter breakpoint according to CLSI 2023 ≤ 20 mm), was found to have G2576T and G2602T mutations in the Domain V of 23S rRNA gene (Table 2). A novel G2694C mutation in addition to the same two G2576T and G2602T mutations, both in domain V of the 23S rRNA gene, were identified in *S. haemolyticus* strain *SZ-7* with a linezolid IZD less than 1 mm.

Previous studies have already reported the G2576T and G2602T substitutions in the Domain V of the 23S rRNA gene of linezolid-resistant *Staphylococcus spp.* [2,7,12,13,14,24]. Although both mutations were first reported in 2007 and in 2021, respectively [2,25], this is the first report of these mutations in *S. haemolyticus* isolated in Egypt. The novel mutation G2694C, whether it plays a role in linezolid resistance is uncertain and needs further confirmation. Nevertheless, this revelation

may have the potential to contribute valuable insights into investigating the mechanism of linezolid resistance caused by mutations in the V domain of 23S rRNA gene.

cfr gene in both isolates was detected and confirmed by sequencing the amplicons on both strands. At Kasr-El-Eini Teaching Hospital, isolations of a cfr-carrying clinical *S. haemolyticus* isolates from the ICU units is extremely alerting to us. Our greatest concern is the presence of the cfr gene in both isolates, as its minimal fitness cost allows cells to retain it even in the absence of selection pressure from the antibiotic. Typically, the cfr gene is situated in an unstable genetic environment, either on the chromosome or on multidrug-resistant plasmids [26]. This precarious positioning would facilitate the easy spread of cfr into susceptible populations and other pathogenic bacteria. Moreover, cfr-mediated resistance confers resistance to a wide-spectrum of antibiotics not only linezolid and thus poses a significant challenge to therapeutic options.

Table (2): Mutations detected in the V domain of 23S rRNA gene of the resistant isolates *S. haemolyticus strain SZ-2* and SZ-7.

Strain	ICU	Clinical sample	Vitek 2 results		Coagulase test	Mutations of the Domain V of 23S rRNA gene	MIC (µg/mm) Linezolid	Linezolid IZD (**CLSI 2023**)	cfr gene
			P (%)	C.L					
SZ-2	Yes	Blood	99	E	Negative	G2576T, G2602T	30 µg	< 1 mm	+
SZ-7	Yes	Blood	99	E	Negative	G2576T, G2602T,	30 µg	< 1 mm	+

					G2694C			

P = Probability, C.L = Confidence Level, E = Excellent, IZD = Inhibation zone

diameter; Mutations in 23S rRNA according to *Staphylococcus* numbering

(NR_076257.1)

Although linezolid resistance due to mutations in Domain V of the 23S rRNA

and presence of cfr gene were reported in several staphylococcal species form many

countries around the world such as Spain [27], the USA [28], Brazil [29], Mexico [30],

Japan [31] and Korea [32], this is the first report of these mutations in S.

haemolyticus isolated in Egypt. This first emergence of LRSH in intensive care units

in our hospital during a short period is very worrying, requiring serious measures and

proper surveillance in the healthcare settings to prevent the intrahospital

dissemination of resistant strains. The novel G2694C mutation in Domain V of the

23S rRNA, whether it plays a role in linezolid resistance is uncertain and needs

further confirmation. Nevertheless, this revelation may have the potential to

contribute valuable insights into investigating the mechanism of linezolid resistance

caused by mutations in Domain V of the 23S rRNA. The study emphasizes the need

for proper surveillance of cfr-carrying strains in the healthcare settings in Egypt.

Data availability

All sequenced data was uploaded to the NCBI under accession numbers PP525131-

PP525132 for *cfr* genes and PP506638- PP506639 for 23S ribosomal RNA gene of *S.*

haemolyticus strain SZ-2 and SZ-7 respectively.

Acknowledgements

Not applicable.

Ethical approval

Ethical approval was granted by the Review Board of the Clinical and Chemical

Pathology Department, Faculty of Medicine, Cairo University, Egypt prior to the

beginning of the study with a waiver of informed consents.

Disclosure statement

The authors declare that there are no conflicts of interest.

Funding

Not applicable.

ORCID

Abdullah El-nagish: https://orcid.org/0000-0002-5704-5475

References

[1] Czekaj, T., Ciszewski, M., & Szewczyk, E. M. (2015). Staphylococcus

haemolyticus – An emerging threat in the twilight of the antibiotics age.

Microbiol. (United Kingdom, *161*, 2061–2068.

[2] Gostev, V., Leyn, S., Kruglov, A., Likholetova, D., Kalinogorskaya, O., Baykina,

M., & Sidorenko, S. (2021). Global expansion of linezolid-resistant coagulase-

negative staphylococci. *Frontiers in Microbiology*, *12*, 661798.

[3] Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H., & Vester, B. (2005). A

new mechanism for chloramphenicol, florfenicol and clindamycin resistance:

Methylation of 23S ribosomal RNA at A2503. *Molecular microbiology*, *57*(4),

1064–1073.

[4] Giessing, A. M. (2009). Identification of 8-methyladenosine as the modification

catalyzed by the radical SAM methyltransferase Cfr that confers antibiotic

resistance in bacteria. *RNA*, *15*, 327–336.

[5] Long, K. S., & Vester, B. (2012). Resistance to linezolid caused by modifications

at its binding site on the ribosome. *Antimicrobial Agents and Chemotherapy*,

56(2), 603–612.

[6] Sadowy, E. (2018). *Linezolid resistance genes and genetic elements enhancing*

their dissemination in enterococci and streptococci. Plasmid.

[7] Zhou, W., Niu, D., Gao, S., Zhong, Q., Liu, C., Liao, X., & Shen, H. (2023).

Prevalence, biofilm formation, and mass spectrometric characterization of

linezolid-resistant Staphylococcus capitis isolated from a tertiary hospital in

China. *Journal of Global Antimicrobial Resistance*, *33*, 155–163.

[8] Yoo, I. Y., Kang, O. K., Shim, H. J., Huh, H. J., & Lee, N. Y. (2020). Linezolid

resistance in methicillin-resistant Staphylococcus aureus in Korea: High rate

of false resistance to linezolid by the VITEK 2 system. *Annals of Laboratory*

Medicine, *40*(1), 57–62.

[9] Han, X., Zou, G., Liu, J., Yang, C., Du, X., Chen, G., & Jiang, X. (2022).

Mechanisms of linezolid resistance in Staphylococcus capitis with the novel

mutation C2128T in the 23S rRNA gene in China. *BMC Microbiology*, *22*(1),

203.

[10] Maarouf, L., Omar, H., El-Nakeeb, M., & Abouelfetouh, A. (2021). Prevalence

and mechanisms of linezolid resistance among staphylococcal clinical isolates

from Egypt. *European Journal of Clinical Microbiology & Infectious*

Diseases, *40*, 815–823.

[11] Almeida, L. M., Lincopan, N., Araújo, M. R. E., & Mamizuka, E. M. (2012).

Clonal dissemination of linezolid-resistant Staphylococcus haemolyticus

exhibiting the G2576T mutation in the 23S rRNA gene in a tertiary care

hospital in Brazil. *Antimicrobial Agents and Chemotherapy*, *56*(5), 2792.

[12] Balandin, B., Lobo, B., Orden, B., Román, F., García, E., Martínez, R., ... &

Galdos, P. (2016). Emergence of linezolid-resistant coagulase-negative

staphylococci in an intensive care unit. *Infectious Diseases*, *48*(5), 343-349.

[13] Hegstad, K., Longva, J. Å., Hide, R., Aasnæs, B., Lunde, T. M., & Simonsen, G.

S. (2014). Cluster of linezolid-resistant Enterococcus faecium ST117 in

Norwegian hospitals. *Scandinavian journal of infectious diseases*, *46*(10),

712-715.

[14] Mazzariol, A., Kocsis, E., Bragagnolo, L., Pellizzer, G., Rassu, M., & Cornaglia,

G. (2012). Co-infection by two linezolid-resistant coagulase-negative

staphylococci with two different resistance determinants. *Scandinavian*

journal of infectious diseases, *44*(12), 978-981.

[15] Toh, S.-M. (2007). Acquisition of a natural resistance gene renders a clinical

strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic

antibiotic linezolid. *Mol. Microbiol*, *64*, 1506–1514.

[16] LaMarre, J. M., Locke, J. B., Shaw, K. J., & Mankin, A. S. (2011). Low fitness

cost of the multidrug resistance gene cfr. *Antimicrob. Agents Chemother*, *55*,

3714–3719.

[17] Kateete, D. P., Kimani, C. N., Katabazi, F. A., Okeng, A., Okee, M. S., &

Nanteza, A. (2010). Identification of Staphylococcus aureus: DNase and

Mannitol salt agar improve the efficiency of the tube coagulase test, Ann.

Clin. Microb. Antimicrob, *9*, 23.

[18] Boerlin, P., Kuhnert, P., Hussy, D., & Schaellibaum, M. (2003). Methods for

identification of Staphylococcus aureus isolates in cases of bovine mastitis. *J*

Clin Microbiol, *41*, 767–771.

[19] Hudzicki, J. (2009). Kirby-Bauer disk diffusion susceptibility test protocol.

American society for microbiology, *15*, 55–63.

[20] CLSI, M. (2023). *Performance Standards for Antimicrobial Susceptibility*

Testing (33rd ed.).

[21] White, T. J., Bruns, T., Lee, S. J. W. T., & Taylor, J. (1990). Amplification and

direct sequencing of fungal ribosomal RNA genes for phylogenetics. *PCR*

Protocols: A Guide to Methods and Applications, *18*, 315–322.

[22] Meka, V. G., Pillai, S. K., Sakoulas, G., Wennersten, C., Venkataraman, L., &

DeGirolami, P. C. (2004). Linezolid resistance in sequential Staphylococcus

aureus isolates associated with a T2500A mutation in the 23S rRNA gene and

loss of a single copy of rRNA. *J Infect Dis*, *190*, 311–317.

[23] Lee, S. M., Huh, H. J., Song, D. J., Shim, H. J., Park, K. S., & Kang, C. I. (2017).

Resistance mechanisms of linezolid-nonsusceptible enterococci in Korea: Low

rate of 23S rRNA mutations in Enterococcus faecium. *J Med Microbiol*, *66*,

1730–1735.

[24] Almeida, L. M., Araújo, M. R. E., Sacramento, A. G., Pavez, M., Souza, A. G.,

Rodrigues, F., & Mamizuka, E. M. (2013). Linezolid resistance in Brazilian

Staphylococcus hominis strains is associated with L3 and 23S rRNA

ribosomal mutations. *Antimicrobial Agents and Chemotherapy*, *57*(8), 4082.

[25] Tarazona, R. E. R., Padilla, T. P., Gómez, J. C. S., Sánchez, J. E. G., &

Hernandez, M. S. (2007). First report in Spain of linezolid non-susceptibility

in a clinical isolate of Staphylococcus haemolyticus. *International Journal of*

Antimicrobial Agents, *3*(30), 277–278.

[26] Gopegui, E. R., Juan, C., Zamorano, L., Perez, J. L., & Oliver, A. (2012).

Transferable multidrug resistance plasmid carrying cfr associated with tet(L),

ant (4')-Ia, and dfrK genes from a clinical methicillin resistant Staphylococcus

aureus ST125 strain. *Antimicrob Agents Chemother*, *56*, 2139–2142.

[27] Morales Kucharski, M. G., Picazo, J. J., Baos, E., Candel, F. J., Arribi, A., Peláez Ros, B., & Sánchez García, M. (2010). *Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.*

[28] Bonilla, H., Huband, M. D., Seidel, J., Schmidt, H., Lescoe, M., McCurdy, S. P., & Quinn, J. P. (2010). Multicity outbreak of linezolid-resistant Staphylococcus epidermidis associated with clonal spread of a cfr-containing strain. *Clinical Infectious Diseases*, *51*, 796–800.

[29] Gales, A. C., Sader, H. S., Andrade, S. S., Lutz, L., Machado, A., & Barth, A. L. (2006). Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. *International Journal of Antimicrobial Agents*, *27*, 300–302.

[30] Mendes, R. E., Deshpande, L., Rodriguez-Noriega, E., Ross, J. E., Jones, R. N., & Morfin-Otero, R. (2010). First report of staphylococcal clinical isolates in Mexico with linezolid resistance caused by cfr: Evidence of in vivo cfr mobilization. *Journal of Clinical Microbiology*, *48*, 3041–3043.

[31] Ikeda-Dantsuji, Y., Hanaki, H., Sakai, F., Tomono, K., Takesue, Y., Honda, J., Nonomiya, Y., Suwabe, A., Nagura, O., & authors. (2011). Linezolid-resistant Staphylococcus aureus isolated from 2006 through 2008 at six hospitals in Japan. *J Infect Chemother*, *17*, 45–51.

[32] An, D., Lee, M. Y., Jeong, T. D., Sung, H., Kim, M. N., & Hong, S. B. (2011). Co-emergence of linezolid-resistant Staphylococcus aureus and Enterococcus faecium in a patient with methicillin-resistant S. aureus pneumonic sepsis. *Diagnostic Microbiology and Infectious Disease*, *69*, 232–233.